A Randomized, Double Blind, Placebo Controlled Study to Assess the Effect of MT-8554 on the Frequency and Severity of Vasomotor Symptoms in Postmenopausal Women
Phase of Trial: Phase II
Latest Information Update: 26 Nov 2018
At a glance
- Drugs Elismetrep (Primary)
- Indications Hot flashes
- Focus Therapeutic Use
- Sponsors Mitsubishi Tanabe Pharma Corporation
- 20 Nov 2018 Status changed from active, no longer recruiting to completed.
- 25 Jul 2018 Status changed from recruiting to active, no longer recruiting.
- 12 Oct 2017 Status changed from not yet recruiting to recruiting.